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a b s t r a c t
The recent identiﬁcation of a novel human coronavirus responsible of a SARS-like illness in the Middle-
East a decade after the SARS pandemic, demonstrates that reemergence of a SARS-like coronavirus from
an animal reservoir remains a credible threat. Because SARS is contracted by aerosolized contamination
of the respiratory tract, a vaccine inducing mucosal long-term protection would be an asset to control
new epidemics. To this aim, we generated live attenuated recombinant measles vaccine (MV) candidates
expressing either the membrane-anchored SARS-CoV spike (S) protein or its secreted soluble ectodomain
(Ssol). In mice susceptible to measles virus, recombinant MV expressing the anchored full-length S
induced the highest titers of neutralizing antibodies and fully protected immunized animals from
intranasal infectious challenge with SARS-CoV. As compared to immunization with adjuvanted
recombinant Ssol protein, recombinant MV induced stronger and Th1-biased responses, a hallmark of
live attenuated viruses and a highly desirable feature for an antiviral vaccine.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Severe acute respiratory syndrome (SARS) is a newly emerged,
human infectious disease that ﬁrst appeared in China in late 2002.
Between November 2002 and July 2003, the virus spread to 29
different countries on 5 continents and was responsible for 8096
clinical cases, leading to 774 deaths (WHO, 2004). WHO case
management guidelines and restricted travel advices allowed to
bring SARS under control by July 2003. The etiological agent of
SARS was identiﬁed as a novel coronavirus, named SARS-
associated coronavirus (SARS-CoV) (Drosten et al., 2003; Ksiazek
et al., 2003) that is genetically distinct from previously character-
ized members of the Coronaviridae family (Rota et al., 2003).
During the 2002–2003 outbreak, SARS-CoV has been isolated in
Chinese civets and racoon dogs (Guan et al., 2003) from which the
virus was likely introduced into the human population (Kan et al.,
2005; Song et al., 2005). Other SARS-CoV-like viruses sharing
more than 88% nucleotide identities with SARS-CoV have been
isolated from Chinese horseshoe bats, which have therefore been
proposed to represent a natural reservoir host of SARS-CoV
(Li et al., 2005). To date, endemic bat SARS-CoV-like viruses have
also been detected in Africa and Europe (for review: Balboni et al.,
2012), and reemergence of a SARS-like disease from an animal
reservoir remains a credible public health threat. An efﬁcient
vaccine would be the most effective way to control a new
epidemic.
Similar to other coronaviruses, SARS-CoV is an enveloped,
positive-stranded RNA virus whose replication takes place in the
cytoplasm of infected cells. Viral particles are composed of four
major structural proteins: the nucleoprotein (N), the small envel-
ope protein (E), the membrane protein (M), and the large spike
protein (S). The spike protein is a type-I transmembrane glyco-
protein of 1255 amino acids. It assembles into homotrimers at the
surface of viral particles, and gives the virion its crown-like
appearance (Neuman et al., 2006). Each monomer (180 kDa) is
composed of a signal sequence (a.a. 1–14), a large ectodomain (a.a.
15–1190) with 23 potential N-glycosylation sites, a transmembrane
domain (a.a. 1191–1227), and a short cytoplasmic tail of 28 a.a.
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(Ksiazek et al., 2003; Rota et al., 2003). The S protein is responsible
for viral entry, binds to the cellular receptor ACE2 (Li et al., 2003) and
mediates fusion between the viral and cellular membranes
(Petit et al., 2005; Simmons et al., 2005). Structurally, the
N-terminal globular head (S1 domain, a.a. 1–680) contains the
receptor-binding region (Wong et al., 2004), and the membrane-
anchored stalk region (S2 domain, a.a. 727–1255) mediates oligo-
merization and fusion (Petit et al., 2005). Similarly to other corona-
viruses, cleavage of the S protein by proteases into its S1 and S2
subunits is required for activation of the membrane fusion domain
following binding to target cell receptors (Matsuyama et al., 2010;
Simmons et al., 2005).
Due to its critical involvement in receptor recognition, as well
as virus attachment and entry, the S protein is the most promising
and studied candidate antigen for SARS-CoV vaccine development.
It is the major target for neutralizing antibodies in human patients
(He et al., 2005; Nie et al., 2004) and in animal models (Buchholz
et al., 2004; Tripp et al., 2005). Passive transfer of IgG from
convalescent SARS patients enhanced the recovery of acute phase
patients when administered within 15 days after the onset of
symptoms (Cheng et al., 2005; Yeh et al., 2005). Administration of
S-speciﬁc antibodies, including monoclonal antibodies, to naïve
animals conferred protection against a subsequent SARS-CoV
infection, demonstrating that the antibodies alone can protect
against SARS in mice (Bisht et al., 2004), hamsters (Roberts et al.,
2006), ferrets (ter Meulen et al., 2004) and Rhesus macaques
(Miyoshi-Akiyama et al., 2011). Accordingly, several candidate
vaccines relying on the induction of spike-speciﬁc neutralizing
antibodies, including DNA vaccines (Callendret et al., 2007; Yang
et al., 2004), live viral vectors (Buchholz et al., 2004; Chen et al.,
2005; Kapadia et al., 2005), live attenuated vaccines (Lamirande
et al., 2008), subunit vaccines (Bisht et al., 2005; He et al., 2006;
Zhou et al., 2006) and inactivated virus vaccine (Stadler et al.,
2005; Zhou et al., 2005), have been reported to induce a protective
immune response in various animal models. Only a few of them
have been evaluated in phase I clinical trials and, lacking a natural
challenge, there is no data on efﬁcacy in humans (Roberts et al.,
2008; Roper and Rehm, 2009).
An ideal vaccine against SARS should induce long-lasting pro-
tective responses after a single administration, be produced at low
cost and scaled up to millions of doses. Live attenuated vaccines are
particularly appropriate for mass vaccination as they are inexpen-
sive to manufacture and induce a strong immunity and long-term
memory after a single injection. To evaluate such a vaccine
approach, we previously developed a vector derived from the
live-attenuated Schwarz strain of measles virus (MV) (Combredet
et al., 2003). MV vaccine is a live-attenuated negative-stranded RNA
virus proven to be one of the safest and most effective human
vaccines. Produced on a large scale in many countries and dis-
tributed at low cost through the Extended Program on Immuniza-
tion (EPI), this vaccine induces life-long immunity to measles after
one or two injections. We previously showed that MV vector stably
expressed different proteins from HIV and ﬂaviviruses and induced
strong and long-term transgene-speciﬁc neutralizing antibodies
and cellular immune responses, even in the presence of preexisting
immunity to MV (Brandler et al., 2007, 2013; Despres et al., 2005;
Guerbois et al., 2009; Lorin et al., 2004). In the present study, we
evaluated the immunogenic potential of recombinant MV-SARS
vectors expressing either the full-length or the secreted ectodomain
of the spike glycoprotein of SARS-CoV. In a mouse model of MV
infection, MV-SARS recombinant viruses induced neutralizing anti-
bodies against SARS-CoV and fully protected immunized animals
from intranasal challenge with SARS-CoV. Antibody responses
induced by MV-SARS vectors were quantitatively and qualitatively
compared to responses induced by a prototype subunit vaccine
prepared from alum-adjuvanted recombinant Ssol protein.
Results
Recombinant MVSchw-SARS viruses express the SARS-CoV spike
glycoprotein, secrete its soluble ectodomain, and replicate efﬁciently
We synthesized human codon-optimized genes encoding the full-
length, membrane anchored SARS-CoV spike (S) protein and its entire
ectodomain (residues 1–1193, hereafter designed as Ssol), which is
expressed in mammalian cells as a soluble and secreted polypeptide
(Callendret et al., 2007, Callendret et al., unpublished results). Their
length respects the “rule of six”, which stipulates that the total number
of nucleotides into theMV genomemust be a multiple of 6 (Calain and
Roux, 1993). MV editing- and polyadenylation-like sequences were
mutated (Lamb and Kolakofsky, 2001; Schneider et al., 1997). Both S
and Ssol sequences were inserted as an additional transcription unit
(ATU) into MV vector (pTM-MVSchw plasmid), which contains an
infectious MV cDNA corresponding to the anti-genome of the Schwarz
vaccine strain (Combredet et al., 2003) (Fig. 1A). The resulting pTM-
MVSchw-S and pTM-MVSchw-Ssol plasmids were transfected into
helper 293-T7-MV cells as previously described (Combredet et al.,
2003). The corresponding recombinant measles viruses MV-S and
MV-Ssol were successfully rescued as indicated by the formation of
syncytia, and then propagated in Vero cell culture. We analyzed the
replication of MV-S and MV-Ssol viruses on Vero cells by using the
same MOI (0.01) than for standard MV stock production (Fig. 1B). The
growth of MV-Ssol was only slightly delayed, compared with that of
parental empty Schwarz MV (MVSchwarz). The ﬁnal yield, routinely
obtained at 60 h post-infection, was high and identical to that of
parental MVSchwarz (106 TCID50/ml). Viral growth and yield of MV-S
were more affected than that of MV-Ssol. This may be due to reduced
MV budding because of the insertion of full length S at the surface of
the infected cells, as already observed for MV expressing membrane-
anchored forms of HIV1 gp160 (Lorin et al., 2004).
We analyzed the expression of SARS-CoV spike antigens by
indirect immunoﬂuorescence (IFA) of Vero cells infected by recom-
binant viruses and by immunoblotting of infected-cell lysates. At
48 h post-infection, IFA performed on permeabilized cells using an
anti-S hyperimmune mouse ascitic ﬂuid revealed a strong expres-
sion of both full-length S and entire ectodomain Ssol of the spike
protein along the compartments of the secretory pathway in
measles-induced syncytia (Fig. 1C, upper panels). When infected
cells were not permeabilized before labeling, only the cell surface of
MV-S induced syncytia was readily stained, indicating that the
membrane-anchored S is efﬁciently transported to the surface
(Fig. 1C, lower panels). Western blot analysis of cell lysates and
supernatants using rabbit anti-S polyclonal antibodies conﬁrmed
the expression of S and Ssol proteins in recombinant MV-infected
Vero cells with the expected apparent molecular mass of 180 kDa
(Fig. 1D, left panel). Under reducing SDS-PAGE conditions the full
length S protein migrates as a doublet, which was described as two
differentially glycosylated forms (Song et al., 2004). The lighter
product was suggested to be an ER-resident form of the glycopro-
tein and the heavier a Golgi-processed form containing complex
carbohydrates. Other bands of lower molecular weight were also
observed that probably correspond to minor degradation fragments,
since they were not present at earlier time points (not shown).
Expression levels were similar in lysates of MV-infected Vero-NK
cells and SARS-CoV infected VeroE6 cells. As expected, the full-
length S protein was only detected in cell lysates. In contrast, Ssol
was clearly detected both in lysate and supernatant of MV-Ssol
infected Vero cells at 40 h after infection (Fig. 1D, right panel),
indicating an efﬁcient secretion. Consistently, the Ssol protein
secreted in the cell culture medium was heavier than the Ssol
observed within cell lysates, which is in agreement with this
glycoprotein being synthesized in an immature form in the ER
prior to transfer to the Golgi, from which it is secreted.
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MV-S and MV-Ssol induce Th1-type immune response and SARS-CoV
neutralizing antibodies in mice
The immunogenicity of the recombinant MVSchwarz-SARS viruses
was investigated in genetically modiﬁed CD46-IFNAR mice susceptible
to MV infection (Mrkic et al., 1998) and compared to the immuno-
genicity of puriﬁed Ssol polypeptide produced in mammalian cells,
which constitutes a potential subunit vaccine candidate against SARS
(Du et al., 2008). The CD46-IFNAR mice express CD46, the human
receptor for vaccine MV strains, and lack the INF-α/β receptor. They
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Fig. 1. Characterization of MVSchw-SARS recombinant viruses expressing the full-length transmembrane spike glycoprotein (S) or its secreted ectodomain (Ssol).
(A) Schematic representation of the pTM-MVSchw-ATU2 vector containing the Schwarz MV cDNAwith a green ﬂuorescent protein (eGFP) gene as an additional transcription
unit (ATU). Codon-optimized synthetic genes coding for the full-length S protein or secreted ectodomain (Ssol) were inserted into pTM-MVSchw between the BsiWI and
BssHII sites of the ATU, in place of the eGFP gene. MV genes are indicated: N (nucleoprotein), PVC (phoshoprotein and V/C accessory proteins), M (matrix), F (fusion),
H (hemaglutinin), L (polymerase). T7: T7 RNA polymerase promoter. hhR: hammerhead ribozyme. T7t: T7 RNA polymerase terminator. h∂vR: hepatitis delta virus (HDV)
ribozyme. (B) Growth kinetics of recombinant MVSchw-SARS viruses. Vero cells were infected with the parental MVSchw (open circles) or recombinant MV-S (ﬁlled squares)
or MV-Ssol (ﬁlled triangles) viruses at an M.O.I. of 0.01. At the indicated time points, cells were collected and cell-associated virus titers were determined as described in
Materials and methods. (C) Immunostaining of spike polypeptides in syncytia of MVSchw-SARS-infected Vero cells. Cells were ﬁxed 24–48 h after infection with the
indicated viruses and permeabilized with triton X-100 (upper panels) or non-permeabilized (lower panels), then labeled as described in Materials and methods with anti-S
mouse polyclonal antibodies and Cy3-conjugated anti-mouse IgG antibodies. (D) Lysates and supernatants of Vero-NK cells infected with MVSchw-SARS viruses were
analyzed by western blot as described in Materials and methods using rabbit polyclonal antibodies speciﬁc for the S protein. As controls, whole cell lysates prepared from
uninfected or SARS-CoV infected VeroE6 cells were analyzed. The positions of full-length S and Ssol polypeptides as well as molecular weight markers (kDa) are shown.
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have been used previously as a model to evaluate the immunogenicity
of recombinant MV (Brandler et al., 2007; Combredet et al., 2003;
Despres et al., 2005; Guerbois et al., 2009; Lorin et al., 2004). Eight to
twelve-week-old male CD46-IFNAR mice were immunized with two
intraperitoneal (i.p.) injections at 4-week interval of 105 TCID50 of MV-
S or MV-Ssol recombinant viruses. As controls, a group of mice was
injected with empty MV vector (105 TCID50) and another group with
2 mg of puriﬁed Ssol protein adjuvanted with 50 mg of aluminum
hydroxide (alum), usual doses for small rodents. Mice sera were
collected three weeks after each injection. SARS-CoV- and measles-
speciﬁc antibody responses were evaluated for each individual mouse
by indirect ELISA against SARS-CoV and MV native antigens,
respectively.
Signiﬁcant titers of anti-SARS IgG were raised in all mice after
the ﬁrst injection of recombinant MV-SARS viruses, whereas
preimmune sera (not shown) and sera from control animals that
received empty MVSchw remained negative (Fig. 2A). These titers
were higher for both MV-S and MV-Ssol injected animals (average
titer of 3.170.3 and 2.770.1 log 10, respectively) than for animals
immunized with Alum-adjuvanted Ssol protein (2.170.3 log 10
titer, po103). After the second injection, titers were boosted 10–
20 times for animals immunized with MV vectors. Tallying with
the results observed after the ﬁrst injection, MV-S induced the
highest IgG titers (4.470.5 log 10, po0.1). MV-Ssol induced
similar titers (3.870.2 log 10) than alum-adjuvanted Ssol protein
(3.870.3 log 10). Interestingly, antibodies to MV were raised at
similar levels in all mice that received either MVSchw or MV-SARS
viruses (Fig. 2B), indicating that expression of the heterologous S
protein by the recombinant viruses did not alter their replication
in vivo nor modify their measles-speciﬁc immunogenicity.
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Fig. 2. Antibody response in IFN-α⧸βR/ CD46þ / mice immunized with MVSchw-SARS recombinant viruses. Groups of 6 IFN-α⧸βR / CD46þ / mice were injected twice
intraperitoneally at four-week interval with 105 TCID50 of the indicated recombinant MVSchw-SARS measles viruses or with parental MVSchw, as control. Another group of
mice was immunized with two intramuscular injections of 2 mg of puriﬁed Ssol polypeptide adjuvanted with 50 mg Alum. Sera were collected before immunization (PI) or
3 weeks after each injection (IS1 and IS2, respectively). SARS-CoV-speciﬁc (A) or MV-speciﬁc (B) IgG antibody titers were determined by indirect ELISA, as described in
Materials and methods. (C) SARS-CoV-speciﬁc, IgG1 (ﬁlled circles) and IgG2a (open circles) isotype titers were determined for each IS2 serum by indirect ELISA. (D) SARS-
CoV-speciﬁc IgA antibody titers were determined for each IS2 serum by indirect ELISA. Values obtained for each individual mouse are represented with circles, with means
for each group of mice shown by horizontal bars. Detection limits of the assays are indicated by dotted lines.
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Additionally, the quality of the humoral response induced by
the various immunogens was studied on sera collected 3 weeks
after the second injection by IgG and IgA isotype analysis and
neutralization assay. We ﬁrst determined the speciﬁc IgG1 and
IgG2a isotype titers to the SARS-CoV antigens by anti-SARS ELISA
(Fig. 2C). The immunizations with the alum-adjuvanted Ssol
protein almost exclusively induced IgG1, indicating that the
induced immune responses are predominantly of Th2-type as we
previously observed in BALB/c mice (Callendret et al., unpublished
results). Contrariwise, MV-S and MV-Ssol viruses induced signiﬁ-
cantly higher titers of IgG2a than IgG1 antibodies, particularly for
MV-S (average ratio IgG2a over IgG1 of 14.7 and 2.7 respectively),
reﬂecting a predominant Th1-type immune response induced by
the live recombinant measles vector. Interestingly, MV-Ssol and
MV-S viruses also induced moderate (2.470.3 log 10) to high
titers (3.270.3 log 10) of anti-SARS IgA antibodies respectively
(Fig. 2D), whereas sera from animals immunized with alum-
adjuvanted Ssol protein remained negative (log 10 titero1.7).
We then further examined whether the antibody response had
SARS-CoV neutralizing activity, which represents the unique
correlate of protective immunity against SARS (Enjuanes et al.,
2008; Roberts et al., 2008). Neutralizing titers were determined by
using an infectivity reduction assay as the highest serum dilution
that suppressed SARS-CoV cytopathic effect in at least 50% of the
inoculated wells of cultured FRhK-4 cells (Fig. 3). Immunization
with MV-Ssol and alum-adjuvanted Ssol protein induced compar-
able level of neutralizing antibodies (2.470.3 and 2.670.3 log 10
titer, respectively), whereas MV-S induced signiﬁcantly three- to
four-fold higher neutralizing titers (3.070.4 log 10 titer, po0.1).
Immunization with recombinant MV-SARS protects from intranasal
experimental challenge
To determine whether immunization by recombinant MV-SARS
could induce protection from an experimental challenge, mice
were inoculated intranasally with 105 pfu of SARS-CoV ﬁve weeks
after the second immunization. Mice inoculated with empty
MVSchw were used as controls. To evaluate the level of protection
against viral replication, we quantiﬁed the SARS-CoV infectious
titers in lung homogenates prepared two days after challenge
(Fig. 4). Control mice immunized with empty MVSchw were all
infected except one, SARS-CoV replicating in their lungs at titers
up to 106 pfu/lung. This shows that CD46-IFNAR mice are suscep-
tible to intranasal SARS-CoV infection, in agreement with previous
observations describing a self-limited bronchiolitis with mild or
moderate pneumonitis in 129/Sv mice (Hogan et al., 2004) and no
increase in susceptibility, pathogenesis and histological outcomes
in IFNAR mice of the same genetic background (Frieman et al.,
2010).
On the contrary, all mice immunized with MV-S were fully
protected from challenge. The absence of SARS-CoV replication
was conﬁrmed by quantitative real-time RT-PCR, which evidenced
more than a 1000-fold reduction of SARS-CoV RNA levels in the
lungs of MV-S-immunized mice (log 10 geq/lungso3.8, below the
detection level) compared to MVSchw-immunized mice
(7.671.9 log 10 geq/lungs). Mice immunized with MV-Ssol or
adjuvanted Ssol were also protected, albeit less efﬁciently; one
mouse in either group had low residual viral titers in the lungs
(Fig. 4) and SARS-CoV RNA remained detectable albeit at strongly
reduced levels in the lungs of half of the immunized mice (not
shown).
Altogether, these experiments demonstrate that recombinant
MV-SARS viruses expressing either the full-length or the secreted
ectodomain of the spike protein induced neutralizing antibodies to
SARS-CoV at titers that were sufﬁcient to protect animals from
experimental intranasal infection. Noticeably, the efﬁciency of
protection followed the hierarchy observed for neutralization
antibody levels, MV-S conferring complete and better protection
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Fig. 3. Neutralizing antibody response in IFN-α⧸βR/ CD46þ / mice immunized
with MVSchw-SARS recombinant viruses. SARS-CoV neutralizing antibody titers
were determined for each IS2 serum as the reciprocal of the highest dilution of
serum which completely prevented SARS-CoV cytopathic effect in 50% of the wells.
Values obtained for each individual mouse are represented with circles, with
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Fig. 4. Protection of MVSchw-SARS-immunized mice from intranasal challenge
with SARS-CoV. Five weeks after the second injection of MVSchw-SARS recombi-
nant viruses or Ssol polypeptide, mice were subjected to intranasal challenge with
105 pfu of SARS-CoV. SARS-CoV infectious titers (expressed as log10 pfu/lungs for
individual mice) were dermined in lung homogenates collected two days after
challenge, using plaque assay on Vero cells. Values for each individual mouse are
represented with ﬁlled circles, and means for each group by horizontal bars. The
detection limits of the assays are indicated by dotted lines. Data shown are from
one experiment representative of two.
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from virus replication in mice lungs than both MV-Ssol and the
reference adjuvanted subunit vaccine.
Discussion
The objective of this study was to evaluate the proof-of-concept
of a new SARS-CoV vaccine strategy based on a standard measles
vaccine engineered to express the SARS-CoV spike protein. This
strategy might provide a safe recombinant vaccine to protect from
SARS-CoV in the regions that might become affected by SARS-CoV
re-emergence.
Due to its critical role in viral entry, the S protein is the most
promising candidate antigen for SARS-CoV vaccine development
(Enjuanes et al., 2008; Roberts et al., 2008; Roper and Rehm,
2009). We designed human codon-optimized genes encoding the
full-length SARS-CoV spike (S) protein and its soluble ectodomain
(Ssol). These sequences were inserted into MV vector. Recombi-
nant viruses were produced by reverse genetics and grew at
standard titers. They expressed high levels of SARS-CoV full-length
spike protein at the cell membrane and led to efﬁcient secretion of
the soluble ectodomain. Immunization of mice susceptible to MV
with recombinant MV-S and MV-Ssol viruses induced speciﬁc
antibodies that neutralized SARS-CoV infection in vitro. The
induction of measles-speciﬁc immunity was not altered by the
expression of the transgenes. Immunization primed a SARS-CoV-
speciﬁc memory response that was vigorously boosted by a second
injection. The anchored full-length form of the spike protein
induced the highest titers of neutralizing antibodies, as we
previously observed with HIV gp160 (Lorin et al., 2004), and also
a more robust response than a prototype subunit vaccine prepared
from adjuvanted recombinant Ssol protein. As compared to
immunization with adjuvanted Ssol protein, both recombinant
MV-SARS viruses induced higher titers of IgG2a than IgG1 anti-
bodies, indicating a Th1 biased response, a hallmark of live
attenuated viruses and a highly desirable feature for an antiviral
vaccine. Remarkably, both recombinant MV-SARS vectors also
induced SARS-CoV speciﬁc IgA, whereas the subunit reference
vaccine did not. This raises an interesting point since several
clinical studies already evidenced that parenteral administration
of live attenuated measles vaccine to children stimulates secretory
IgA responses in nasal washes (Bellanti et al., 2004; Simon et al.,
2011). Although we did not assess the ability of recombinant MV-
SARS to induce secretory IgA in the lungs and upper respiratory
tract of immunized mice, this result is strongly indicative of the
potential of MV-SARS to induce SARS-CoV speciﬁc secretory IgA
responses.
To evaluate the efﬁcacy of recombinant MV-SARS vectors, we
relied on challenge with wt human SARS-CoV and evaluation of
lung virus titers since, unfortunately, mouse-adapted SARS-CoV is
not lethal in 129/Sv mice (Frieman et al., 2010). After two
successive immunizations with recombinant MV-S virus, all mice
were fully protected from intranasal infectious challenge with
SARS-CoV and neither infectious virus nor residual viral RNA could
be recovered from the lungs of the challenged animals. Interest-
ingly, despite a lower replication rate in cell culture, MV-S
conferred a better protection from SARS-CoV replication in mice
lungs than MV-Ssol. This may reﬂect better immunogenicity of the
native anchored-form of S or suggest structural dissimilarities
between the monomeric soluble Ssol ectodomain and its corre-
sponding membrane-associated trimeric form. In that respect, the
absence, or inefﬁcient presentation, of antibody epitopes on
truncated soluble immunogens derived from functional virion-
associated glycoproteins has already been evidenced for ﬁlovirus
attachment proteins (Sullivan et al., 2006) and HIV gp160
(Davenport et al., 2011; Kovacs et al., 2012).
Usually given intramuscularly, measles vaccine protects very
efﬁciently against measles disease, which is contracted by aero-
solized contamination of the upper respiratory tract, similarly to
SARS. Our data demonstrate that parenteral immunization with
MV-SARS vector protected mice lungs from SARS-CoV intranasal
infection. A similar approach was previously reported by Liniger
et al. (2008) that also demonstrated the induction of neutralizing
antibodies in mice to SARS-CoV spike expressed by a MV vector.
However, this study did not evaluate the efﬁcacy of vaccine
preparation to protect immunized mice from SARS-CoV challenge.
Our observation that MV-SARS induced a strong Th1 response
appears of particular importance given the recently reported
safety concerns by Tseng et al., which described Th2-type lung
immunopathology upon challenge of mice vaccinated with inacti-
vated whole virus, SARS VLP or alum-adjuvanted S protein (Tseng
et al., 2012). They suggested that most previously described
vaccine-induced immunopathology might proceed from the same
Th2-type immunopathology with prominent eosinophil inﬁltra-
tion upon SARS-CoV challenge. Such effects will likely not occur
with live vaccines since they induce potent Th1-biased responses.
In agreement with this hypothesis, it was recently reported that a
live attenuated SARS-CoV lacking E protein expression provided
long-term protection against lethal challenge in an aged-mice
model in the absence of any sign of vaccine-induced immuno-
pathology (Fett et al., 2013).
Live attenuated RNA virus vaccines like those against mumps,
measles, polio or rubella viruses induce long-term cell-mediated
and humoral immunity after one or two injections. Using MV as a
vaccination vector presents a number of advantages: this highly
efﬁcient and most safe vaccine is easily produced at large scale,
vaccine strains are genetically stable, MV does not recombine or
integrate genetic material, vaccine does not persist or diffuse. The
Schwarz/Moraten strain from which we derived our vector
(Combredet et al., 2003) is currently the most attenuated and
the most widely used measles vaccine. Measles vector expresses
very stably large amounts of heterologous genetic material, likely
due to the absence of geometric constraints on the size of
helicoidal nucleocapsids in this pleiomorphic virus (Tangy and
Naim, 2005). Although the stability of expression of the speciﬁc
SARS transgene remains to be determined, the remarkable genetic
stability of added, expressed ORFs has already been described by
us and others for a variety of transgenes inserted into measles
vector and other members of the Mononegavirales. The measles
vector demonstrated a strong capacity to stimulate both cellular
and humoral neutralizing immunity against a number of antigens
and provided protection from experimental challenge both in mice
and primates (Brandler et al., 2007, 2012; Despres et al., 2005;
Lorin et al., 2004; Tangy and Naim, 2005). A measles-HIV vaccine
candidate currently under clinical development has been evalu-
ated in phase I clinical trial, demonstrating the GMP preclinical
and clinical safety and immunogenicity of this vector (Lorin et al.,
2012; Stebbings et al., 2012).
Recombinant MV vaccines might be used to immunize both the
pediatric and adult/adolescent populations in case of SARS-CoV
outbreaks. The presence of anti-MV immunity in nearly the entire
adult human population might restrict the use of recombinant MV
to naïve infants, an already worthy goal in any event. However,
numerous studies have shown that revaccinating immunized
individuals results in a boost of anti-MV antibodies, suggesting
that the attenuated live vaccine replicates and expresses its
proteins in spite of preexisting immunity (Dilraj et al., 2000;
Rager-Zisman et al., 2003; Sepulveda-Amor et al., 2002). Likewise,
the presence of maternal anti-MV antibodies has been shown to
limit the induction of anti-measles antibodies but not the induc-
tion of speciﬁc T-cell responses in infants given measles vaccine
during the ﬁrst year of life (Gans et al., 2003, 2001). Moreover, we
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previously demonstrated that recombinant MV vectors were
immunogenic and induced protection in the presence of MV
preexisting immunity in animal models (Brandler et al., 2013;
Lorin et al., 2004), which opens the possibility of using recombi-
nant MV vector to immunize adolescents and adults, although this
point needs to be evaluated in human trials. Measles appears very
difﬁcult to eliminate and still causes 160,000 deaths annually
worldwide, mostly in poorly developed countries (Centers for
Disease and Prevention, 2009). Europe also recently experienced
severe measles outbreaks (Cottrell and Roberts, 2011). Improving
and maintaining measles vaccination for decades is essential to
contain this most contagious disease. In this context, the use of
recombinant MV designed to immunize the pediatric or adult
populations appears desirable.
In conclusion, we have produced new recombinant MV-SARS
viruses able to induce neutralizing antibodies to SARS-CoV and full
protection from intranasal challenge, thus making the proof-of-
concept of this strategy for SARS vaccine development and more
generally for severe respiratory infectious diseases. These char-
acterized SARS vaccine candidates deserve to be evaluated in a
much more adapted non-human-primate model, in which the
cross-protective potential of the induced immune responses
against zoonotic SARS isolates/variants could be addressed.
Indeed, several studies have underlined the need to induce
broadly neutralizing antibodies able to protect against heterolo-
gous viral variants, which may arise during independent emer-
gence events (Bolles et al., 2011; Sheahan et al., 2011). Such
antigenic variants have already been isolated from animals during
the 2002–2003 epidemics and from sporadic human cases during
the 2003–2004 reemergence (Deming et al., 2006; Yang et al.,
2005), and are likely to emerge again from the large heteroge-
neous zoonotic reservoir of SARS-like viruses, should a new out-
break occur. The recent identiﬁcation of a novel human
betacoronavirus, MERS-CoV, as the agent of a SARS-like illness in
the Middle-East, has raised great concerns about the pandemic
potential of the disease (Perlman, 2013; WHO, 2013; Zaki et al.,
2012). A decade after the SARS pandemic, it has renewed world-
wide attention on coronaviruses and stressed the need of con-
tinued research and investment in the development of safe and
effective vaccines against highly pathogenic coronaviruses.
Materials and methods
Cell lines, viruses and antigens
FRhK-4 (Fetal Rhesus monkey Kidney) and Vero-NK (African
Green Monkey Kidney) cells were grown at 37 1C under 5% CO2 in
complete DMEM [Dulbecco0s modiﬁed Eagle medium with 4.5 mg/
ml L-glucose, 100 U/ml penicillin and 100 mg/ml streptomycin],
supplemented with 5% heat-inactivated fetal calf serum (FCS)
(DMEM-5). Helper 293-T7-MV cells stably expressing T7 RNA
polymerase and N and P genes from Schwarz MV were grown in
complete DMEM supplemented with 10% FCS (DMEM-10).
SARS-CoV FFM-1 strain (Drosten et al., 2003) was kindly
provided by Dr. H.W. Doerr (Institute of Medical Virology, Frank-
furt University Medical School, Germany). Viral stocks were
produced and titrated as described previously (Callendret et al.,
2007). All work involving infectious SARS-CoV was performed in
an enhanced biosafety level 3 containment laboratory with rigor-
ous safety procedures according to WHO guidelines.
Crude cell lysates prepared from SARS-CoV infected VeroE6
cells and inactivated frozen by gamma irradiation, as described
(Callendret et al., 2007), were used as SARS native antigens for
ELISA. A soluble monomeric spike protein, termed Ssol and
corresponding to the entire S ectodomain (residues 1–1193) fused
with the FLAG tag was produced and puriﬁed by immunoafﬁnity
chromatography (Sigma-Aldrich) from the supernatant of stable
mammalian cell lines (Callendret et al., unpublished results).
Construction and rescue of recombinant MVSchw-SARS viruses
A human codon-optimized gene encoding the SARS-CoV spike
(S) protein of the ♯031589 specimen (Callendret et al., 2007) was
chemically synthesized by Geneart (Regensburg, Germany) and
subcloned into the pCI mammalian expression vector (Promega),
yielding plasmid pCI-Ssynth. In addition to codon bias optimiza-
tion, regions of very high (480%) or low (o30%) GC content were
avoided whenever possible. Furthermore, cis-acting sequence
motifs such as internal TATA-boxes, chi-sites, ribosomal entry
sites, ARE, INS, and CRS sequence elements, as well as repetitive
sequences, RNA secondary structures and splice donor and accep-
tor sites, were avoided. The resulting optimized gene had an
increased GC content (61.7% from 38.9%). The sequence of the
codon-optimized S gene is available upon request. A codon-
optimized gene encoding the soluble and secreted spike ectodo-
main (Ssol) was obtained by PCR ampliﬁcation using the
pCI-Ssynth plasmid as a template and oligonucleotides 50-
ACTAGCTAGC GGATCCACCA TGTTCATCTT CCTG-30 containing
Nhe-1 restriction site (underlined) and 50-AGTATCCGGA CTTGATG-
TAC TGCTCGTACT TGC-30 containing BspE1 restriction site. The
PCR fragment was inserted into pCI-Ssol which contains the wild-
type non-optimized gene encoding Ssol (Callendret et al., unpub-
lished data), yielding plasmid pCI-Scube.
Measles recombinant vector was derived from plasmid pTM-
MVSchw-ATU2 which carries an infectious cDNA corresponding to
the anti-genome of the Schwarz MV vaccine strain and an
additional transcription unit containing unique restriction sites
for the insertion of foreign sequences downstream of the P gene
(Combredet et al., 2003) (Fig. 1A). The full-length (S) and secreted
(Ssol) spike sequences were ampliﬁed by PCR using the pCI-Ssynth
or pCI-Scube plasmids as templates and oligonucleotides
50-ATAGGATCCC GTACGACCAT GTTCATCTTC CTGCTGTTC-30 con-
taining BsiWI restriction site (underlined) and 50-ATAGGATCCG
CGCGCTTATC AGGTGTAGTG CAGCTTCAC-30 or 50-ATAGGATCCG
CGCGCTCATT ATTTATCGTC GTCATCTTTA TAATC-30 containing
BssHII restriction site (underlined). After digestion with BsiWI
and BssHII restriction enzymes, the resulting DNA fragments were
inserted into the corresponding sites of pTM-MVSchw-eGFP. The
sequences inserted into the MV vector respect the “rule of six”,
which stipulates that the number of nucleotides of the MV
genome must be a multiple of 6 (Calain and Roux, 1993;
Schneider et al., 1997). The resulting plasmids pTM-MVSchw-S
and pTM-MVSchw-Ssol were used to rescue recombinant viruses
using a helper-cell-based system as previously described
(Combredet et al., 2003). Single viral clones were ampliﬁed on
Vero-NK cells. All viral stocks were stored at 80 1C and titrated
by an endpoint limiting dilution assay on Vero-NK cell mono-
layers. Growth curves of recombinant and parental viruses were
determined on Vero-NK cells infected at an M.O.I. of 0.01, as
described (Combredet et al., 2003).
Analysis of spike protein expression in infected cells
For indirect immunoﬂuorescence assays, monolayers of Vero-
NK cells plated on 20 mm glass coverslips in a 12-well plate were
infected with the recombinant MVSchw-SARS or parental MV-
Schw viruses at a multiplicity of infection (M.O.I.) of 0.05. When
syncytia were clearly visible but not yet conﬂuent (24–48 h after
infection) cells were washed in D-PBS, ﬁxed with PBS-4% paraf-
ormaldehyde for 15 min and in some instances permeabilized
with PBS-0.2% triton X-100 for 10 min. Coverslips were then
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incubated for 60 min with anti-Ssol hyperimmune mouse ascitic
ﬂuid diluted 1/1000 in PBS-1% donkey serum (DKS). After sub-
sequent incubation with a Cy3-conjugated anti-mouse IgG sec-
ondary antibody (Jackson Immunoresearch), the samples were
mounted on slides with DAPI-containing Vectashield (Vector
laboratory) and analyzed under an Axioplan 2 epiﬂuorescence
microscope (Zeiss). Pictures were acquired with an Axiocam MRm
camera and processed with the Axiovision software (v 4.2, Zeiss).
For western blot assays, cytosolic cell extracts were prepared
from Vero-NK cells infected with the recombinant MVSchw-SARS
or parental MV-Schw viruses, essentially as described previously
(Lorin et al., 2004). Proteins were separated by 8% SDS-poly-
acrylamide gels and transferred onto a PVDF membrane prior to
immunoblotting with rabbit anti-S antibodies, as described
(Callendret et al., 2007).
Mice experiments and characterization of humoral immune responses
All experiments were approved and conducted in accordance to
the Pasteur Institute guidelines in compliance with European
animal welfare regulations. To obtain CD46þ / IFNα/ßR / mice
permissive for measles vaccine (Mrkic et al., 1998), FVB mice
heterozygous for the measles vaccine CD46 receptor transgene
were backcrossed to 129/Sv mice lacking the type IFN (Combredet
et al., 2003). After more than 10 generations of backcrossing in our
breeding colony, the resulting CD46-IFNAR line acquired a uniform
129/Sv background.
Six- to nine-week-old CD46-IFNAR mice were used to assess
the immune response induced by recombinant MVSchw-SARS.
Groups of 6 mice were injected intraperitoneally (i.p.) with 105
TCID50 of recombinant MVSchw-SARS or parental MVSchw. Con-
trol groups of mice were injected intramuscularly with formula-
tions containing 2 mg of puriﬁed Ssol polypeptide and 50 mg
aluminum hydroxide (Alu-Gel-S, Serva). Booster injections were
administered 4 weeks thereafter. Serum samples were collected
one week before immunization and 3 weeks after each injection
(PI, IS1 and IS2 sera).
We measured the induction of SARS-CoV speciﬁc antibodies in
immunized mice by indirect ELISA and neutralization assay, as
described previously (Callendret et al., 2007). Brieﬂy, microtiter
plates were coated with SARS-CoV infected or mock-infected
VeroE6 crude cell lysates and incubated with serial dilutions of
the test sera. Bound antibodies were revealed with mouse-speciﬁc
anti-IgG (1/2000, Amersham) secondary antibody coupled to
horseradish peroxidase and TMB (3,30-5,50-tetramethylbenzidine,
KPL). Readings from wells coated with mock lysates were sub-
stracted from wells with SARS-CoV lysates and the SARS-CoV
speciﬁc IgG titers were calculated as the reciprocal of the highest
dilution of individual serum, giving an absorbance of 0.5. The
isotype determination of the antibody responses was performed
using isotype-speciﬁc (IgG1 and IgG2a) secondary antibodies
coupled to horseradish peroxidase (Southern Biotech). IgA titers
were similarly measured using mouse-speciﬁc anti-IgA secondary
antibody (1/2000, Southern Biotech) and calculated as the reci-
procal of the highest dilution of individual serum, giving an
absorbance of 0.2. MV speciﬁc antibodies were similarly measured
using ELISA plates coated with puriﬁed measles antigens (Trinity
Biotech, USA). For neutralization, two-fold serial dilution of heat-
inactivated serum samples were incubated at 37 1C for 60 min
with 100 TCID50 of SARS-CoV and added to a subconﬂuent
monolayer of FRhK-4 cells in a 96-well microtiter plate. Each
dilution of serumwas tested in quadruplicate and cytopathic effect
(CPE) endpoints were read up to 7 days after inoculation. Neu-
tralizing antibody titers were determined according to the Reed
and Muench method (Reed and Muench, 1938) as the reciprocal of
the highest dilution of each serum, which suppressed CPE in at
least 2 out of 4 wells.
Challenge infection of animals with SARS-CoV
Five weeks after the second immunization, animals were ligh-
tly anesthetized with Isoﬂurane (Mundipharma) and inoculated
intranasally with 105 pfu of SARS-CoV in 40 ml PBS. Mice were
euthanized 48 h after challenge infection. Lung homogenates were
prepared in 500 ml DMEM supplemented with 2% FCS and titrated
for infectious virus on VeroE6 monolayers, as described
(Callendret et al., 2007). Viral RNAwas extracted using the QIAamp
Viral RNA Mini kit (Qiagen) from 100 ml of tissue homogenates
according to the manufacturer0s recommendations, eluted in 60 ml
of RNAse-free water and analyzed by real-time RT-PCR, as
described below. Challenge infection of all animals and subsequent
analysis involving infectious materials were done in the “Jean
Merieux” biosafety level 4 containment laboratory. Statistical
analysis was performed on the log 10 of the viral titers measured
for individual mice using the Student0s independent t-test,
with the assumptions used for small samples (normal distribution
of the variables and same variance for the populations to be
compared).
SARS-CoV genome RNA quantiﬁcation by real-time RT-PCR
SARS-CoV genome RNA levels in tissue RNA samples were
quantiﬁed by real-time RT-PCR with the PRISM 7700 sequence
detection system. Brieﬂy, RNA samples (2 ml) were reverse-
transcribed and ampliﬁed with the TaqMans One Step PCR Master
Mix Reagents Kit (Applied Biosystems) according to the man-
ufacturer0s recommendations, in combination with primer set and
ﬂurorogenic probe speciﬁc for the nucleoprotein (N) gene (Drosten
et al., 2004). Reactions were performed in thermo-fasts 96-well
reaction plates (Abgene) with 25 ml mixtures containing 2 ml of
template RNA, 300 nM concentration (each) of primers SANS1 (50-
TGGACCCAC AGATTCAAC TGA-30) and SANPAs2 (50-GCTGTGAAC
CAAGACGCA GTAT-30) (Eurogentec), and a 100 nM concentration of
probe SANP1 (6-FAM-TAACCAGAATGGAGGACGCAATGG-TAMRA)
(Eurogentec). The cycling conditions were 45 1C for 15 min, fol-
lowed by 95 1C for 5 min and then 45 cycles of 95 1C for 15 s and
60 1C for 60 s. Fluorescence was read at the combined annealing-
extension step at 60 1C. Absolute quantiﬁcation of RNA was done
by using in vitro transcribed RNA standards prepared from the
cloned SARS-CoV N gene and quantiﬁed spectrophotometrically.
Analytical sensitivity of this real-time N RT-PCR assay was experi-
mentally determined by using limiting serial dilutions of the N
RNA standard. Using probit non-linear regression analysis, the 95%
detection limit of the RT-PCR was calculated at 40 copies of input
RNA per reaction, which corresponded to 3.8 log 10 virus genome-
equivalent (geq) per mouse tissue, assuming 100% efﬁciency in
RNA preparation.
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